• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by Recursion Pharmaceuticals Inc. (Amendment)

    2/12/24 12:21:25 PM ET
    $RXRX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $RXRX alert in real time by email
    SC 13G/A 1 tm245872d2_sc13ga.htm SC 13G/A

     

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    WASHINGTON, DC 20549

     

     

     

    SCHEDULE 13G

     

    UNDER THE SECURITIES EXCHANGE ACT OF 1934

    (Amendment No. 1)*

     

    Recursion Pharmaceuticals, Inc.

    (Name of Issuer)

     

    Class A Common Stock

    (Title of Class of Securities)

     

    75629V104

    (CUSIP Number)

     

    January 31, 2024

    (Date of Event Which Requires Filing of this Statement)

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

     

    x  Rule 13d-1(b)

    ¨  Rule 13d-1(c)

    ¨  Rule 13d-1(d)

     

    * The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

     

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     

     

     

     

    CUSIP No. 75629V104 13G Page 2 of 5 Pages 

     

    1. NAMES OF REPORTING PERSONS    
    ARK Investment Management LLC    
       
    2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP    
    (a)☐    
    (b)☐    
    3. SEC USE ONLY    
         
       
    4. CITIZENSHIP OR PLACE OF ORGANIZATION    
    Delaware, United States    
       
    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON WITH
    5. SOLE VOTING POWER    
     22,042,084    
       
    6. SHARED VOTING POWER    
     594,078    
       
    7. SOLE DISPOSITIVE POWER    
     23,076,052    
       
    8. SHARED DISPOSITIVE POWER    
    0    
       
    9. AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON    
     23,076,052    
       
    10. CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES    
    ☐    
       
    11. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)    
    11.08%    
       
    12. TYPE OF REPORTING PERSON    
    IA    
       
               

     

     

     

     

    CUSIP No. 75629V104 13G Page 3 of 5 Pages 

     

    Item 1(a) Name of issuer: 

     

    Recursion Pharmaceuticals, Inc.

      

    Item 1(b) Address of issuer's principal executive offices: 

     

    41 S Rio Grande Street

    Salt Lake City, UT 84101

     

    Item 2(a) Name of person filing: 

     

    ARK Investment Management LLC

     

    Item 2(b) Address or principal business office or, if none, residence:

     

    ARK Investment Management LLC

    200 Central Avenue

    St. Petersburg, FL 33701

     

    Item 2(c) Citizenship: 

     

    Delaware, United States 

     

    Item 2(d) Title of class of securities:  

     

    Common Stock

     

    Item 2(e) CUSIP No.:

     

    75629V104

     

    Item 3. If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:

     

    (a) ¨ Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);

     

    (b) ¨ Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);

     

    (c) ¨ Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);

     

    (d) ¨ Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C 80a-8);

     

    (e) x An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);

     

    (f) ¨ An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);

     

    (g) ¨ A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);

     

    (h) ¨ A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);

     

    (i) ¨ A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);

     

    (j) ¨ A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J);

     

    (k) ¨ Group, in accordance with § 240.13d-1(b)(1)(ii)(K). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution: ____

     

     

     

     

    CUSIP No. 75629V104 13G Page 4 of 5 Pages 

     

    Item 4. Ownership 

     

    (a)Amount beneficially owned:

     

    23,076,052

     

    (b)Percent of class:

     

    11.08%

     

    (c)Number of shares as to which such person has:

     

    (i)  Sole power to vote or to direct the vote: 22,042,084

     

    (ii) Shared power to vote or to direct the vote:  594,078

     

    (iii) Sole power to dispose or to direct the disposition of: 23,076,052

     

    (iv) Shared power to dispose or to direct the disposition of:  0

     

    Item 5. Ownership of 5 Percent or Less of a Class.

     

    Not applicable.

      

    Item 6. Ownership of More than 5 Percent on Behalf of Another Person.

     

    To the knowledge of the Reporting Person, no other person has the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, a number of the shares which represents more than five percent of the number of outstanding class of the shares.

     

    Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.

     

    Not applicable.

     

    Item 8. Identification and Classification of Members of the Group.

     

    Not applicable.

     

    Item 9. Notice of Dissolution of Group.

     

    Not applicable.

     

    Item 10. Certifications.

     

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.

     

     

     

     

    CUSIP No. 75629V104 13G Page 5 of 5 Pages 

     

    SIGNATURE

     

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

    The reporting persons agree that this statement is filed on behalf of each of them.

     

    Dated:    February 12, 2024

     

      ARK Investment Management LLC  
         
      By: /s/ Kellen Carter
        Name: Kellen Carter
        Title: Chief Compliance Officer

     

     

     

    Get the next $RXRX alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $RXRX

    DatePrice TargetRatingAnalyst
    12/17/2025$11.00Neutral → Overweight
    Analyst
    7/3/2025$5.00Equal-Weight
    Morgan Stanley
    5/22/2023$8.00Equal-Weight
    Morgan Stanley
    3/16/2023$17.00Buy
    Needham
    9/16/2022$20.00Overweight
    KeyBanc Capital Markets
    4/18/2022$10.00Buy → Neutral
    BofA Securities
    3/4/2022$32.00 → $10.00Outperform → Market Perform
    SVB Leerink
    12/8/2021$30.00 → $32.00Outperform
    SVB Leerink
    More analyst ratings

    $RXRX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Gibson Christopher converted options into 40,000 shares and sold $123,200 worth of shares (40,000 units at $3.08) as part of a pre-agreed trading plan (SEC Form 4)

    4 - RECURSION PHARMACEUTICALS, INC. (0001601830) (Issuer)

    5/27/26 4:15:15 PM ET
    $RXRX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    CEO and President Khan Najat covered exercise/tax liability with 62,701 shares, decreasing direct ownership by 3% to 2,199,384 units (SEC Form 4) (for withholding tax)

    4 - RECURSION PHARMACEUTICALS, INC. (0001601830) (Issuer)

    5/19/26 5:54:50 PM ET
    $RXRX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Chief Scientific Officer Hallett David covered exercise/tax liability with 26,657 shares, decreasing direct ownership by 2% to 1,070,494 units (SEC Form 4) to cover withholding tax

    4 - RECURSION PHARMACEUTICALS, INC. (0001601830) (Issuer)

    5/19/26 5:54:56 PM ET
    $RXRX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $RXRX
    SEC Filings

    View All

    SEC Form SCHEDULE 13G filed by Recursion Pharmaceuticals Inc.

    SCHEDULE 13G - RECURSION PHARMACEUTICALS, INC. (0001601830) (Subject)

    5/12/26 11:53:03 AM ET
    $RXRX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 10-Q filed by Recursion Pharmaceuticals Inc.

    10-Q - RECURSION PHARMACEUTICALS, INC. (0001601830) (Filer)

    5/6/26 6:32:40 AM ET
    $RXRX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Recursion Pharmaceuticals Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - RECURSION PHARMACEUTICALS, INC. (0001601830) (Filer)

    5/6/26 6:31:39 AM ET
    $RXRX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $RXRX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Recursion Pharmaceuticals upgraded by Analyst with a new price target

    Analyst upgraded Recursion Pharmaceuticals from Neutral to Overweight and set a new price target of $11.00

    12/17/25 8:47:25 AM ET
    $RXRX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Morgan Stanley resumed coverage on Recursion Pharmaceuticals with a new price target

    Morgan Stanley resumed coverage of Recursion Pharmaceuticals with a rating of Equal-Weight and set a new price target of $5.00

    7/3/25 7:50:07 AM ET
    $RXRX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Morgan Stanley initiated coverage on Recursion Pharmaceuticals with a new price target

    Morgan Stanley initiated coverage of Recursion Pharmaceuticals with a rating of Equal-Weight and set a new price target of $8.00

    5/22/23 7:50:41 AM ET
    $RXRX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $RXRX
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Recursion to Participate in Upcoming Investor Conferences

    Salt Lake City, UT, June 02, 2026 (GLOBE NEWSWIRE) -- Recursion (NASDAQ:RXRX), a leading clinical-stage TechBio company decoding biology to radically improve lives, today announced its participation in an upcoming investor conference: Goldman Sachs 47th Annual Global Healthcare Conference — Tuesday, June 9, 2026 Webcasts may be found in the events section of the Recursion Investor Relations website at ir.recursion.com. About RecursionRecursion (NASDAQ:RXRX) is a clinical-stage TechBio company decoding biology to radically improve lives. Recursion is advancing a portfolio of differentiated investigational medicines across its wholly owned and partnered pipeline in oncolog

    6/2/26 8:00:00 AM ET
    $RXRX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Recursion Reports Grant of Inducement Awards as Permitted by the Nasdaq Listing Rules

    Salt Lake City, UT, May 29, 2026 (GLOBE NEWSWIRE) -- Recursion (NASDAQ:RXRX), a leading clinical stage TechBio company decoding biology to radically improve lives, announced that on May 26, 2026, the Compensation Committee of Recursion's Board of Directors approved the grant of inducement restricted stock unit (RSU) awards covering 2,991,840 shares of its class A common stock in the aggregate to 33 new employees under Recursion's 2024 Inducement Equity Incentive Plan (the "2024 Plan"). Each award was granted as an inducement material to the employee's commencement of employment with Recursion, or a subsidiary of Recursion, pursuant to Nasdaq Listing Rule 5635(c)(4). Each inducement RSU

    5/29/26 4:30:00 PM ET
    $RXRX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Altitude Lab Portfolio Companies Surpass $205 Million in Funding, Marking a New Era for Early-Stage Biotechs in Salt Lake City

    SALT LAKE CITY, May 19, 2026 (GLOBE NEWSWIRE) -- Altitude Lab, the platform-first biotech-startup accelerator founded by Recursion (NASDAQ:RXRX), announced today that its portfolio companies have collectively raised more than $205 million in early-stage funding since the program's launch in 2020. The milestone reflects a portfolio of companies advancing into clinical trials, signing deals with global pharma, and commercializing platform technologies reshaping the boundaries of early-stage biotech despite this difficult funding climate. Dr. Joshua Schiffman, CEO/Co-founder of Peel Therapeutics, credits their success to initial support from Altitude Lab, "With Altitude Lab serving as our bi

    5/19/26 12:07:00 PM ET
    $RXRX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $RXRX
    Leadership Updates

    Live Leadership Updates

    View All

    Altitude Lab Portfolio Companies Surpass $205 Million in Funding, Marking a New Era for Early-Stage Biotechs in Salt Lake City

    SALT LAKE CITY, May 19, 2026 (GLOBE NEWSWIRE) -- Altitude Lab, the platform-first biotech-startup accelerator founded by Recursion (NASDAQ:RXRX), announced today that its portfolio companies have collectively raised more than $205 million in early-stage funding since the program's launch in 2020. The milestone reflects a portfolio of companies advancing into clinical trials, signing deals with global pharma, and commercializing platform technologies reshaping the boundaries of early-stage biotech despite this difficult funding climate. Dr. Joshua Schiffman, CEO/Co-founder of Peel Therapeutics, credits their success to initial support from Altitude Lab, "With Altitude Lab serving as our bi

    5/19/26 12:07:00 PM ET
    $RXRX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Recursion Announces Vicki Goodman, M.D., as Incoming Chief Medical Officer

    Salt Lake City, UT, March 25, 2026 (GLOBE NEWSWIRE) -- Recursion (NASDAQ:RXRX), a leading clinical-stage TechBio company decoding biology to radically improve lives, today announced that Vicki Goodman, M.D., will become Recursion's Chief Medical Officer effective April 6, 2026 as David Mauro, M.D., Ph.D. transitions out of the role. As Recursion advances its pipeline and prepares for key clinical and regulatory milestones, which are consistent with previously communicated expectations, Dr. Goodman brings a rare and differentiated perspective of how to translate scientific promise into successful clinical programs. Her experience spans executive roles in biotech and large pharma, with p

    3/25/26 7:59:00 AM ET
    $RXRX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    PacBio Announces the Appointment of Chris Gibson to the Board of Directors

    MENLO PARK, Calif., March 05, 2026 (GLOBE NEWSWIRE) -- PacBio (NASDAQ:PACB), a leading provider of high-quality, long-read sequencing technologies, today announced the appointment of Christopher Gibson, Ph.D., to PacBio's Board of Directors. Dr. Gibson is the co-founder and Chairman of the Board of Directors of Recursion (NASDAQ:RXRX), a clinical-stage biotechnology company that has built one of the industry's most advanced AI-driven drug discovery platforms. Under his leadership, Recursion integrated large-scale biological data generation with machine learning to industrialize the discovery process, building a vertically integrated technology stack spanning automation, high-dimensional b

    3/5/26 8:30:00 AM ET
    $PACB
    $RXRX
    Biotechnology: Laboratory Analytical Instruments
    Industrials
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $RXRX
    Financials

    Live finance-specific insights

    View All

    Recursion to Report First Quarter 2026 Business Updates and Financial Results on May 6

    Salt Lake City, UT, April 29, 2026 (GLOBE NEWSWIRE) -- Recursion (NASDAQ:RXRX), a leading clinical stage TechBio company decoding biology to radically improve lives, announced today it will provide business updates and report its first quarter 2026 financial results on Wednesday, May 6, 2026, before the open of the financial markets. Recursion will host an Earnings Call on May 6, 2026 at 8:00 am ET / 6:00 am MT / 1:00 pm BST. The company will broadcast the live stream from Recursion's X, LinkedIn, and YouTube accounts. Investors, analysts, and the public will be able to ask questions of the company by submitting questions here: https://forms.gle/TQ4vgUTLKsFmikcu6.  About RecursionR

    4/29/26 7:59:00 AM ET
    $RXRX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Recursion to Report Fourth Quarter and Full Year 2025 Business Updates and Financial Results on February 25

    Salt Lake City, UT, Feb. 18, 2026 (GLOBE NEWSWIRE) -- Recursion (NASDAQ:RXRX), a leading clinical stage TechBio company decoding biology to radically improve lives, announced today it will provide business updates and report its fourth quarter and full year 2025 financial results on Wednesday, February 25, 2026, before the open of the financial markets. Recursion will host a (L)earnings Call on February 25, 2026 at 8:00 am ET / 6:00 am MT / 1:00 pm GMT. The company will broadcast the live stream from Recursion's X, LinkedIn, and YouTube accounts. Investors, analysts, and the public will be able to ask questions of the company by submitting questions here: https://forms.gle/TQ4vgUTLKsFm

    2/18/26 8:30:00 AM ET
    $RXRX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Recursion to Report Third Quarter 2025 Business Updates and Financial Results on November 5th

    Salt Lake City, UT, Oct. 28, 2025 (GLOBE NEWSWIRE) -- Recursion (NASDAQ:RXRX), a leading clinical stage TechBio company decoding biology to radically improve lives, announced today it will provide business updates and report its third quarter 2025 financial results on Wednesday, November 5, 2025, before the open of the financial markets.Recursion will host a (L)earnings Call on November 5, 2025 at 8:00 am ET / 6:00 am MT / 1:00 pm GMT. The company will broadcast the live stream from Recursion's X, LinkedIn, and YouTube accounts. Investors, analysts, and the public will be able to ask questions of the company by submitting questions here: https://forms.gle/TQ4vgUTLKsFmikcu6.About RecursionR

    10/28/25 8:00:00 AM ET
    $RXRX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $RXRX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Recursion Pharmaceuticals Inc.

    SC 13G/A - RECURSION PHARMACEUTICALS, INC. (0001601830) (Subject)

    11/12/24 4:57:06 PM ET
    $RXRX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: SEC Form SC 13G/A filed by Recursion Pharmaceuticals Inc.

    SC 13G/A - RECURSION PHARMACEUTICALS, INC. (0001601830) (Subject)

    11/12/24 10:34:18 AM ET
    $RXRX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: SEC Form SC 13G/A filed by Recursion Pharmaceuticals Inc.

    SC 13G/A - RECURSION PHARMACEUTICALS, INC. (0001601830) (Subject)

    11/4/24 4:16:21 PM ET
    $RXRX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care